Erasca Reports Third Quarter 2026 Business Updates and Financial Results

Erasca, Inc. (ERAS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Erasca Reports Third Quarter 2026 Business Updates and Financial Results ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Updated ERAS

Event · Earnings
Original reporting
Published Nov 12, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ERAS
Bullish
high confidence
Mentioned
$ERAS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ERASBullishHigh
01

Why it matters

The disclosed financing and regulatory milestone improve liquidity and de‑risk the pipeline, likely supporting the share price.

02

Market read

First‑report 8‑K provides fresh financials and FDA news, making the article highly relevant for traders.

03

What to watch

Potential dilution from the $632.5M raise and execution risk of upcoming Phase 3 trials.

Relevance 8/10Novelty 8/10Timing: same-day release
AlphAI · Earnings readERAS · Q3 2026 · ended 2026-09-30

Erasca reports Q3 2026 net loss of $51.3 million as R&D spend rises; cash of $947.8 million; ERAS-0015 receives FDA Fast Track Designation for metastatic pancreatic adenocarcinoma

→Mixed quarter

The filing reports no revenue line. Net loss widened from $30.6 million to $51.3 million, with R&D up from $22.5 million to $47.2 million, and nine-month results include $150.0 million of in-process R&D. Cash, cash equivalents and marketable securities rose to $947.8 million from $341.8 million at December 31, 2025, and the company states this is sufficient to fund its listed milestones.

EPS · GAAP
$(0.15)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expense, Q3 2026 (three months ended September 30, 2026)GAAP$47.2M––
General and administrative expense, Q3 2026 (three months ended September 30, 2026)GAAP$12.3M––
In-process research and development, Q3 2026 (three months ended September 30, 2026)GAAPno amount shown (dash in statement of operations)––
Total operating expenses, Q3 2026 (three months ended September 30, 2026)GAAP59.52M––
Loss from operations, Q3 2026 (three months ended September 30, 2026)GAAP−59.52M––
Interest income, Q3 2026 (three months ended September 30, 2026)GAAP8.26M––
Total other income (expense), net, Q3 2026 (three months ended September 30, 2026)GAAP8.19M––
Net loss, Q3 2026 (three months ended September 30, 2026)GAAP$51.3M––
Net loss per share, basic and diluted, Q3 2026 (three months ended September 30, 2026)GAAP$(0.15)––
Comprehensive loss, Q3 2026 (three months ended September 30, 2026)GAAP−54.27M––
Research and development expense, nine months 2026 (nine months ended September 30, 2026)GAAP110.4M––
In-process research and development, nine months 2026 (nine months ended September 30, 2026)GAAP150M––
General and administrative expense, nine months 2026 (nine months ended September 30, 2026)GAAP34.69M––
Total operating expenses, nine months 2026 (nine months ended September 30, 2026)GAAP295.1M––
Loss from operations, nine months 2026 (nine months ended September 30, 2026)GAAP−295.1M––
Interest income, nine months 2026 (nine months ended September 30, 2026)GAAP16.32M––
Total other income (expense), net, nine months 2026 (nine months ended September 30, 2026)GAAP16.20M––
Net loss, nine months 2026 (nine months ended September 30, 2026)GAAP−278.9M––
Net loss per share, basic and diluted, nine months 2026 (nine months ended September 30, 2026)GAAP$(0.87)––
Comprehensive loss, nine months 2026 (nine months ended September 30, 2026)GAAP−283.7M––
Cash, cash equivalents, and marketable securities (as of September 30, 2026)other$947.8M––
Total assets (as of September 30, 2026)other998.9M––
Total stockholders' equity (as of September 30, 2026)other916.7M––

Capital returns

  • No share repurchases or dividends are reported in the filing.

What drove it

  • The company states that the R&D increase was primarily driven by higher expenses for clinical trials, preclinical studies, discovery activities, personnel costs including stock-based compensation, outsourced services, and consulting fees.
  • The company states that the G&A increase was primarily driven by personnel costs, including stock-based compensation expense.
  • The filing reports that interest income was 8,264 (in thousands) in Q3 2026 against 3,971 (in thousands) in Q3 2025, and that other income (expense) is shown net within total other income.
  • The filing reports 150,000 (in thousands) of in-process R&D for the nine months ended September 30, 2026, against 9,500 (in thousands) in the prior-year nine months, and no in-process R&D amount in Q3 2026.

Concerns

  • Net loss increased from $30.6 million to $51.3 million in the quarter, and nine-month net loss reached (278,850) (in thousands) against (95,454) (in thousands) in the prior-year period.
  • The filing reports no revenue line in its statements of operations.
  • Nine-month results include 150,000 (in thousands) of in-process R&D expense, which the filing presents within operating expenses.
  • The forward-looking statements list the possibility that the company may not successfully defend allegations raised by Revolution Medicines (RevMed) that ERAS-0015 infringes RevMed patents or was derived from RevMed trade secrets, and note that future litigation may be initiated.
  • The timing of the Phase 3 pivotal trial in RASm NSCLC is given as the second half of 2027 to the first half of 2028, and the forward-looking statements note that planned trials may be delayed based on FDA feedback or requirements.
  • The forward-looking statements caution that interim, topline and preliminary results may materially change, and that the FDA retains broad discretion to require additional clinical data before a registrational trial.

What to watch

  • ENA Symposium presentations, November 18 to 20, 2026 in Barcelona: an oral plenary with updated ERAS-0015 monotherapy data from AURORAS-1, and a poster on nonclinical ERAS-0015 and ERAS-4001 combination data.
  • Preliminary ERAS-4001 Phase 1 monotherapy data from BOREALIS-1, expected in the second half of 2026.
  • AURORAS-1 Phase 1 monotherapy expansion data and combination dose escalation data, including the panitumumab combination, both expected in the first half of 2027.
  • Initiation of a potentially registration-enabling trial in second line or greater NSCLC, expected in the first half of 2027.
  • Initiation of the Phase 3 pivotal trial in first line PDAC, expected in 2027.
  • Initiation of BOREALIS-1 monotherapy expansion and combination dose escalation cohorts, planned for 2027.
  • Quarterly R&D and G&A expense levels relative to the Q3 2026 figures of $47.2 million and $12.3 million, and the trajectory of cash, cash equivalents, and marketable securities.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $947.8 million as of September 30, 2026, compared with $341.8 million as of December 31, 2025 (balance sheet data, unaudited).
  • Working capital was 611,200 (in thousands) as of September 30, 2026, compared with 257,728 (in thousands) as of December 31, 2025.
  • Total assets were 998,936 (in thousands) as of September 30, 2026, compared with 396,154 (in thousands) as of December 31, 2025.
  • Total stockholders' equity was 916,738 (in thousands) as of September 30, 2026, compared with 325,171 (in thousands) as of December 31, 2025.
  • Accumulated deficit was (1,171,059) (in thousands) as of September 30, 2026, compared with (892,209) (in thousands) as of December 31, 2025.
  • In July 2026 the company completed an upsized public offering, which the filing states raised approximately $632.5 million in gross proceeds.
  • The company states that its current cash, cash equivalents, and marketable securities will be sufficient to fund the Key Upcoming Milestones listed in the release.

Analysis

Erasca reported results for the fiscal quarter ended September 30, 2026, a period in which the statements of operations show no revenue line. Total operating expenses rose to 59,521 (in thousands) from 34,546 (in thousands) in the year-earlier quarter, and the net loss widened to $51.3 million, or $(0.15) per share, from $30.6 million, or $(0.11) per share. The main line items moving the loss were R&D, at $47.2 million against $22.5 million, and G&A, at $12.3 million against $10.1 million. The company attributes the R&D increase to clinical trial, preclinical, discovery, personnel and outsourced service costs, and the G&A increase to personnel costs including stock-based compensation.

The nine-month picture is more heavily shaped by a single item. Operating expenses for the nine months ended September 30, 2026 were 295,051 (in thousands), against 108,301 (in thousands) a year earlier, and in-process R&D accounted for 150,000 (in thousands) of that total, compared with 9,500 (in thousands) in the prior-year period. Nine-month net loss was (278,850) (in thousands), or $(0.87) per share, against (95,454) (in thousands), or $(0.34) per share. The filing does not provide a breakdown of the in-process R&D charge beyond the statement line itself.

The balance sheet changed materially over the period. Cash, cash equivalents, and marketable securities were $947.8 million at September 30, 2026, against $341.8 million at December 31, 2025, and stockholders' equity rose to 916,738 (in thousands) from 325,171 (in thousands). The release refers to an upsized public offering completed in July 2026 with approximately $632.5 million in gross proceeds, which is the main identified source of the increase. Management states that current cash, cash equivalents and marketable securities will be sufficient to fund the milestones listed in the release. The filing does not include a cash flow statement, so operating or free cash flow for the period cannot be reported.

Operationally, the company highlighted FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma, granted in August 2026, and two presentations at the ENA Symposium in November 2026. It also reported the appointment of a president of research and development and a senior vice president of global pharmacovigilance in August 2026. The milestone schedule runs through 2027 and into 2028, with preliminary ERAS-4001 data expected in the second half of 2026, ERAS-0015 monotherapy and combination data in the first half of 2027, and Phase 3 starts in 2027 and in the second half of 2027 to the first half of 2028. The filing contains no financial guidance for future periods.

The key figures for a reader are the step-up in R&D and G&A, the reported net loss, the $947.8 million cash balance, and the dated milestones. The forward-looking statements also flag the RevMed patent and trade secret allegations and the possibility of trial delays as risks to the schedule.

Management, verbatim

The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens.

Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, and co-founder

With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.

Jonathan E. Lim, M.D., Chairman, Chief Executive Officer, and co-founder

Not in the filing

stated, not guessed
  • No revenue or collaboration revenue line appears in the statements of operations, so no revenue figure is reported.
  • No prior-quarter (Q2 2026) figures are printed, so all qoq_change and prior_quarter fields are null.
  • No percentage changes are printed for any metric, so all yoy_change fields are null.
  • No segment information is reported.
  • No cash flow statement or operating cash flow, investing cash flow, or free cash flow figures are provided.
  • No share repurchase or dividend activity is reported.
  • The filing does not state whether the figures are GAAP or non-GAAP; statement of operations basis is recorded as GAAP on the assumption that these are the reported statement lines.
  • No stock price reaction, consensus estimates, or analyst expectations are included in the documents.
  • Prior-year figures for the balance sheet are as of December 31, 2025, not the same period of the prior year, so balance sheet prior_year fields are null.
  • The July 2026 offering is described only as approximately $632.5 million in gross proceeds; no net proceeds, share count or pricing details are provided.
  • The previous outlook contained only milestone timing and a cash runway statement, with no numeric guidance for Q3 2026 results, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Erasca is a clinical‑stage precision oncology company focused on RAS/MAPK pathway cancers.

Company-level read

Ticker impact

$ERASBullishHigh confidence
Context

Erasca filed an 8‑K reporting Q3 2026 results, including $948M cash, a $632.5M upsized financing, and FDA Fast Track designation for ERAS‑0015.

Expected impact

likely upward pressure as investors price in the strong cash balance and regulatory milestone

Evidence & confidence

New capital raise and regulatory progress are fresh, material facts that can move the stock immediately.

Market effects

Positive signal for the broader precision oncology sector as FDA Fast Track may encourage investor interest.

Limited to US biotech investors; no broader regional effect.

Modest global relevance, primarily affecting biotech and pharma investors.

Counterpoint

The fast‑track designation does not guarantee approval; the high cash burn could pressure margins.

Key entities

  • Erasca, Inc.

    Nasdaq‑listed biotech developing RAS‑targeted therapies.

Every ERAS earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

Low

Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

Tango Therapeutics and Erasca began a Phase I/II trial for ERAS-0015 and vopimetostat combo in lung and pancreatic cancer patients. The trial, sponsored by Tango, aims to find the max tolerated dose and assess safety, tolerability, and antitumour activity. Both companies believe the combo shows promise in treating RAS-driven cancers. ERAS-0015 targets RAS signalling, while vopimetostat inhibits PRMT5.

$ERASHighAI 8/10

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

$ERASHighAI 8/10

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.